Athens, Greece (ots/PRNewswire) - - Approximately 40 percent of people with diabetes develop nephropathy, the leading cause of kidney failure Eli Lilly and Company (NYSE: LLY) today announced encouraging results from a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with ...
Athens, Greece (ots/PRNewswire) - -- Patients on exenatide also lost weight, while glargine patients gained weight -- Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) today announced results from a study indicating that exenatide improves blood sugar levels as effectively as ...
Athens, Greece (ots/PRNewswire) - - Improvements in cardiovascular risk factors were also observed Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) today presented results from a study indicating that the investigational compound exenatide showed sustained improvements in ...
Bayer Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.
West Haven, Connecticut, and Emeryville, California (ots/PRNewswire) - - European Trial to Provide Access to Sorafenib for Individuals with Advanced Renal Cell Carcinoma Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Marketing Authorization Application (MAA) has been submitted by Bayer to the European Medicines Agency (EMEA) in London for the ...
Macclesfield, England (ots/PRNewswire) - Today, new guidelines from the prestigious St. Gallen 'International Consensus Conference on the Primary Therapy of Early Breast Cancer' were released ahead of publication on the Annals of Oncology website(1). For the first time, the St. Gallen consensus panel has ...
New Brunswick, New Jersey (ots/PRNewswire) - Johnson & Johnson (NYSE: JNJ) has been notified that the European Commission has cleared its proposed acquisition of Guidant Corporation (NYSE: GDT). In conjunction with the Commission's clearance, Johnson & Johnson has agreed to divest its Cordis steerable guidewires business in Europe and the Guidant Endovascular ...
London (ots/PRNewswire) - - Winners of the First Embrace Journalism Award for Reporting on Urinary Incontinence and Launch of the Second Embrace Award Announced Three journalists from South Africa, Poland and the United States today received the Embrace Award, a global initiative that recognizes accurate, responsible and sensitive reporting on urinary ...
Lausanne (ots) - In the Forbes' survey of the Best Business Schools, featured in the September 5 edition of the publication, IMD ranked #2 among 1-year non-US MBA programs. For 2005, the top 1-year, non-US MBA programs as ranked by Forbes were: 1. Insead 2. IMD 3. SDA Bocconi 4. Instituto de Empresa 5. Oxford (Said) The survey ranked schools based on return on investment--meaning compensation ...
Beijing and Moscow (ots/PRNewswire) - In the news release, InnoCentive Continues to Grow Its Virtual Scientific Network by Adding Leading Universities Throughout China and Russia, issued earlier today by InnoCentive over PR Newswire, we are advised by the client that the quote in the third graph should be attributed to "Mr. Ali Hussein" rather than "Mr. Hussein" as originally issued inadvertently. Complete, corrected ...
Indianapolis and Ingelheim, Germany (ots/PRNewswire) - The landmark PURE (Prospective Urinary Incontinence REsearch) study data at baseline, presented today at IUGA (International Urogynecological Association), show that many women with symptoms of stress urinary incontinence (SUI) are receiving off-label ...
Macclesfield, England (ots/PRNewswire) - "The results of our data confirm that a switch in therapy from tamoxifen to anastrozole can help us as clinicians to help our patients live cancer-free for longer." Professor Raimund Jakesz Vienna Medical University, Austria Austrian Breast & Colorectal Cancer ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to demonstrate a promising safety and efficacy profile. The Canadian Phase III Psoriasis (SPIRIT) trial commenced on December 2, 2004 and includes a total of 453 patients with ...
Copenhagen, Denmark (ots/PRNewswire) - - International pharmaceutical Company Chooses MCI Private IP, IP Dedicated and Colocation to Link 58 Sites Across Europe, Asia and North and South America MCI, Inc. (Nasdaq: MCIP) today announced that the international pharmaceutical company H. Lundbeck A/S has selected MCI to link 58 of its site across Europe, Asia and North and South America using MCI Private IP, a ...
Rio De Janeiro, Brazil and Ingelheim, Germany (ots/PRNewswire) - - New Data Support its Use as Powerful Treatment Against HIV Drug Resistance RIO DE JANEIRO, Brazil and INGELHEIM, Germany, July 28 /PRNewswire/ -- Boehringer Ingelheim announced today that the CHMP (Committee for Medicinal Products for Human Use) in London has issued a positive opinion for tipranavir, a non-peptidic protease inhibitor, to ...
Madrid (ots/PRNewswire) - PharmaMar: - Orphan Drug designation granted by the FDA to Yondelis for the treatment of ovarian cancer in April. - Patient recruitment ongoing for the Phase III trial of Yondelis in ovarian cancer. - Promising results of Phase II trial of Yondelis in prostate cancer released at ASCO. - PharmaMar received 1 million dollars for complying with a milestone under the licensing and ...
Rio De Janeiro, Brazil (ots/PRNewswire) - - Giving Patients Facing HIV Resistance Their Best Chance to Achieve Undetectable Viral Loads Data presented at IAS build a compelling case for FUZEON (enfuvirtide, formerly known as T-20) to be combined with the newest drugs to give patients facing resistance their best chance of achieving undetectable viral load - the optimal treatment goal for all people living with ...
Swiftwater, Pennsylvania and Lyon, France (ots/PRNewswire) - - First and Only Booster in the US for Protection Against Pertussis From Adolescence Through Adulthood Sanofi Pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN), (NYSE: SNY), announces the availability of Adacel(TM) ...
Bothell, Washington and Indianapolis (ots/PRNewswire) - - Latest figures confirm success of Cialis in the global ED marketplace Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS), marketer of tadalafil(1), a PDE5 inhibitor indicated for the treatment of erectile dysfunction (ED), announced today that the drug has achieved US$1 billion in global sales since ...
Basel, Switzerland (ots/PRNewswire) - - Results Provide New Hope in Fight Against One of the Most Deadly Cancers Treatment with the innovative cancer drug Tarceva(R) in patients with advanced non-small cell lung cancer (NSCLC) resulted in significantly longer survival compared to placebo (42.5% ...
Madrid (ots/PRNewswire) - - In his Previous Position he was Vice President, Clinical Research Oncology at OSI Pharmaceuticals in the US PharmaMar announced today the appointment of Dr. Pedro Santabárbara as Senior Director of the Clinical Development Department. Dr. Santabárbara is a medical ...
Barcelona, Spain (ots/PRNewswire) - - First Inhibitor of VEGF (a) and EGF (b) Signalling to Show Anti-Tumour Activity Both as Monotherapy and in Combination With Chemotherapy AstraZeneca today reported new findings from two Phase II studies, Trials 003 and 006, in the 2nd-line treatment of NSCLC, with ...
Barcelona, Spain (ots/PRNewswire) - AstraZeneca (LSE: AZN, NYSE: AZN) announced today that it is to progress to Phase III studies with its novel oncology compound ZD6474 - now also known by its trade name, ZACTIMA (TM). Recruitment to Phase III studies evaluating the anti-tumour activity of ZACTIMA (TM) (ZD6474) ...
World Federation for Mental Health
Vienna, Austria (ots/PRNewswire) - - World Federation for Mental Health urges better understanding, treatment and management to improve outcomes for people living with bipolar disorder The World Federation for Mental Health (WFMH) today announced results of a global bipolar disorder consumer survey, Thinking Ahead, at the World Congress of Biological Psychiatry. The survey revealed that almost half (47%) of ...
LILLE, France and MONTREAL, Québec, June 28 (ots/PRNewswire) - The latest scientific data on MacoPharma's prion filter device will be presented at the XV European Regional Congress of the International Society of Blood Transfusion (ISBT) being held in Athens, Greece on July 4, 2005, MacoPharma and ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI.SV) announced ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its innovative, oral cancer medicine Tarceva (erlotinib) has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of non-small cell lung cancer, the most common form of lung cancer. "This decision is proof of the impressive ...
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
Milwaukee and Toronto (ots/PRNewswire) - Cedara, a Merge Healthcare company (Nasdaq: MRGE), and a leading independent developer of medical software technologies for the global healthcare market, and their Distributor in the Benelux, ImaXperts BV, have finalized the installation of a new FUSION PACS(TM) for the ...
Madrid (ots/PRNewswire) - Zeltia S.A.(ZEL SM; ZEL.MC), the Spanish biotechnology company, today announces that it has raised Eur 65 million of new funds through a private placement of 10.75 million new ordinary shares with qualified institutional investors at a price of Eur 6.05 per share. This transaction is one of the four largest executed in European biotech in the last four years. The funds raised will be used ...
Madrid, Spain (ots/PRNewswire) - Zeltia S.A, the Spanish consumer chemicals and biotechnology group announces today that its Board of Directors has authorized a capital increase through a private placement with qualified international institutional investors. The capital increase is expected to raise approximately one hundred (100) million euros. A "green shoe" of up to 15% of the amount raised can be exercised by ...
Copenhagen, Denmark (ots/PRNewswire) - - "Approximately five more pregnancies per 100 women treated" with MENOPUR compared to recombinant treatment New data presented today at the ESHRE (European Society of Human Reproduction and Embryology) congress supports the efficacy of MENOPUR (menotrophin), a highly purified, naturally-derived infertility treatment belonging to the class of drugs known as gonadotrophins, ...